T-MSC granted the patent authorization of Japan and Australia
The core technology of ImStem Biotechnology Inc. has recently been granted the patent authorization of the national patent office of Japan and Australia.
News Center
First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS
11/23 . 2021
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
-
25 2018.01
-
09 2017.12
ImStem, UConn Obtain U.S. Patent for Mesenchymal Stem Cell Technology to Treat MS, Other Diseases
The U.S. Patent and Trademark Office has issued a patent for human embryonic stem cell derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production.
-
05 2014.06
ImStem Biotechnology, Inc. Makes Progress on Multiple Sclerosis Treatment with Embryonic Stem Cells
ImStem Biotechnology, Inc.(ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.
-
31 2013.10
Pluripotent stem cell expert Hongkui Deng Joins ImStem's Scientific Advisory Board
ImStem Biotechnology, (ImStem) announced today that Dr. Hongkui Deng, Ph.D. has been appointed to the Company's Scientific Advisory Board.